Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has at least 1 year history of migraine (with or without aura)~* Females of childbearing years must use acceptable contraception throughout trial~Exclusion Criteria:~* Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)~* Patient has history or evidence of uncontrolled diabetes, or Human Immunodeficiency Virus (HIV) disease. Patient has uncontrolled cardiovascular disease~* Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)~* Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption~* Patient has a history of cancer within the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK0974 50 mg (Type: EXPERIMENTAL): MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
- MK0974 150 mg (Type: EXPERIMENTAL): MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
- MK0974 300 mg (Type: EXPERIMENTAL): MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
- Placebo (Type: PLACEBO_COMPARATOR): Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack

Based on this trial design, predict the completion outcome and termination type (if applicable).